CD274 and melanoma: On the basis of the available phase III trials, the KEYNOTE-066 study, demonstrated an overall survival benefit with pembrolizumab in patients with advanced melanoma, as compared to ipilimumab, across all subgroups except for the small subgroup of patients (less than 20%) with PD-L1 negative tumors [48].